Drug Profile


Alternative Names: 115866; R115866; Rambazole

Latest Information Update: 24 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen L.P.
  • Developer Stiefel Laboratories
  • Class Azoles; Small molecules
  • Mechanism of Action Aromatase inhibitors; Cytochrome P 450 enzyme system inhibitors; Retinoic acid metabolism modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Acne; Psoriasis

Most Recent Events

  • 22 Jul 2009 Stiefel Laboratories acquired by GlaxoSmithKline
  • 07 Aug 2008 Barrier Therapeutics acquired by and merged into Stiefel Laboratories
  • 16 Feb 2007 No development reported - Phase-I/II for Skin disorders in Europe (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top